Page 2 - Tom Graney News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Regulated Information Leuven, BELGIUM, Boston, MA, US – October 20, 2023 – 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 29, 2023 – 7.00 PM CET – Oxurion NV , a biopharmaceutical company developing next-generation standard of care ophthalmic...

EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”). On Septe

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 29, 2023 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF.

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 27, 2023 – 7.00 PM CET Oxurion NV , a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...